Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: Incidence, possible pathogenesis and management Journal Article

  

Authors:	Herr, H. W.; Whitmore, W. F. Jr
Article Title:	Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: Incidence, possible pathogenesis and management
Abstract:	A total of 66 patients with multifocal, progressive, flat carcinoma in situ of the bladder responded completely to intravesical bacillus Calmette-Guerin therapy for more than 1 year. Of the patients 19 (29 per cent) had clinical evidence of distal ureteral carcinoma in situ between 13 and 30 months (median 15 months) after bacillus Calmette-Guerin treatment. After evaluation of a positive urinary cytology study failed to reveal recurrent urothelial tumor of the bladder or prostatic urethral mucosa 6 patients underwent distal ureterectomy, 2 underwent nephroureterectomy, and 11 were managed by ureteroscopic resection and fulguration. In patients with carcinoma in situ of the bladder treated successfully with topical therapy the ureters represent a potential site of in situ carcinoma.
Keywords:	major clinical study; pathogenesis; treatment; bcg vaccine; bladder cancer; carcinoma in situ; nephroureterectomy; drug therapy; ureter carcinoma; therapy; urinary tract; bladder; etiology; topical drug administration; superficial cancer; human; priority journal; ureterectomy
Journal Title:	Journal of Urology
Volume:	138
Issue:	2
ISSN:	0022-5347
Publisher:	Elsevier Science, Inc.
Date Published:	1987-08-01
Start Page:	292
End Page:	294; discussion 294
Language:	English
DOI:	10.1016/s0022-5347(17)43123-5
PUBMED:	3599241
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023234578&doi=10.1016%2fS0022-5347%2817%2943123-5&partnerID=40&md5=8079a73b5edfa8532936c42fe7d3b646
Notes:	Article -- Export Date: 5 February 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/177109